Table 1 Study population characteristics by estrogenic botanical supplement (EBS) use

Study site

0.12

   Western Washington

90 (19.4)

70 (23.1)

   New Mexico

259 (55.8)

146 (48.2)

   Los Angeles County

115 (24.8)

87 (28.7)

Race

0.63

   Non-Hispanic white

281 (60.6)

173 (57.1)

   African-American

115 (24.8)

88 (29.0)

   Hispanic

53 (11.4)

33 (10.9)

   Others

15 (3.2)

9 (3.0)

Education

< 0.0001

   ≤ High school

143 (30.8)

51 (16.8)

   Technical school or some college

154 (33.2)

126 (41.6)

   College graduate

167 (36.0)

126 (41.6)

Mean age at diagnosis (SD^b), years

56.0 (10.6)

52.5 (8.7)

< 0.0001 ^c

Stage at diagnosis

0.41

   In situ

110 (23.7)

60 (19.8)

   Localized

257 (55.4)

173 (57.1)

   Regional

97 (20.9)

70 (23.1)

Breast cancer treatment

0.43

   No radiation and no chemotherapy

155 (33.4)

86 (28.4)

   Radiation only

171 (36.9)

116 (38.3)

   Chemotherapy only

45 (9.7)

29 (9.6)

   Radiation and chemotherapy

93 (20.0)

72 (23.8)

Tamoxifen use

0.24

   No

248 (53.5)

175 (57.8)

   Yes

216 (46.6)

128 (42.2)

Medical comorbidity

0.007

   None

332 (71.6)

243 (80.2)

   1 or more condition(s)

132 (28.5)

60 (19.8)

Activity level within the past year of 30-month interview from sports/recreation (MET hours/week)

< 0.0001

   0

93 (20.0)

33 (10.9)

   0.1-8.9

201 (43.3)

115 (38.0)

   ≥ 9

170 (36.6)

155 (51.2)

Menopausal status at 30-month interview

0.01

   Premenopausal

74 (16.0)

68 (22.4)

   Postmenopausal

Never HT^d after diagnosis

193 (41.6)

135 (44.6)

Ever HT^d after diagnosis

172 (37.1)

80 (26.4)

   Unknown

25 (5.4)

20 (6.6)

Body mass index at 30-month interview (kg/m²)

0.13

   < 25

180 (38.8)

128 (42.2)

   25-29

133 (28.7)

97 (32.0)

   ≥ 30

151 (32.5)

78 (25.7)

Mean isoflavones from soy-containing foods (SD^b), mg/day

1.9 (9.4)

4.0 (9.9)

0.002 ^c